Menu Search
Equities

Shanghai Shyndec Pharmaceutical Co Ltd

600420:SHH

Shanghai Shyndec Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)10.08
  • Today's Change-2.65 / -20.82%
  • Shares traded6.25m
  • 1 Year change-1.18%
  • Beta0.8725
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Shanghai Shyndec Pharmaceutical Co Ltd had revenues fall -6.86% from 12.96bn to 12.07bn, though the company grew net income 10.21% from 627.79m to 691.88m.
Gross margin37.73%
Net profit margin11.88%
Operating margin14.23%
Return on assets6.99%
Return on equity8.55%
Return on investment10.16%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Shanghai Shyndec Pharmaceutical Co Ltd fell by 703.83m. However, the company earned 1.72bn from its operations for a Cash Flow Margin of 14.25%. In addition the company used 1.36bn on investing activities and also paid 1.09bn in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share9.75
Tangible book value per share8.97
More ▼

Balance sheet in CNYView more

Shanghai Shyndec Pharmaceutical Co Ltd has a Debt to Total Capital ratio of 10.12%, a higher figure than the previous year's 8.83%.
Current ratio2.51
Quick ratio2.03
Total debt/total equity0.1309
Total debt/total capital0.1012
More ▼

Growth rates in CNY

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items marginally increased 0.07%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)1.05%
Div growth rate (5 year)0.00%
Payout ratio (TTM)24.78%
EPS growth(5 years)-3.41
EPS (TTM) vs
TTM 1 year ago		32.89
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.